Administration, Intravesical
"Administration, Intravesical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.
| Descriptor ID |
D000283
|
| MeSH Number(s) |
E02.319.267.120.505
|
| Concept/Terms |
Administration, Intravesical- Administration, Intravesical
- Intravesical Drug Administration
- Drug Administration, Bladder
- Administration, Intravesical Drug
- Administrations, Intravesical Drug
- Drug Administration, Intravesical
- Drug Administrations, Intravesical
- Intravesical Drug Administrations
- Intravesical Administration
- Administrations, Intravesical
- Intravesical Administrations
- Bladder Drug Administration
- Administration, Bladder Drug
- Administrations, Bladder Drug
- Bladder Drug Administrations
- Drug Administrations, Bladder
Instillation, Bladder- Instillation, Bladder
- Bladder Instillation
- Bladder Instillations
- Instillations, Bladder
- Intravesical Instillation
- Instillation, Intravesical
- Instillations, Intravesical
- Intravesical Instillations
Intravesical Injection- Intravesical Injection
- Injections, Intravesical
- Injection, Intravesical
- Intravesical Injections
|
Below are MeSH descriptors whose meaning is more general than "Administration, Intravesical".
Below are MeSH descriptors whose meaning is more specific than "Administration, Intravesical".
This graph shows the total number of publications written about "Administration, Intravesical" by people in this website by year, and whether "Administration, Intravesical" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 3 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 3 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 4 | 4 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Administration, Intravesical" by people in Profiles.
-
Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Gu?rin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group. Eur Urol Oncol. 2025 Feb; 8(1):216-229.
-
Predicting Response to Intravesical Bacillus Calmette-Gu?rin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort. J Urol. 2025 Feb; 213(2):192-204.
-
Reply: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Oct; 212(4):625.
-
Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Gu?rin Have an Effect? Eur Urol. 2024 Oct; 86(4):366-368.
-
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
-
Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Gu?rin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Gu?rin Treatment. Clin Genitourin Cancer. 2024 Jun; 22(3):102059.
-
Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. 2024 04; 42(4):116.e17-116.e21.
-
A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Gu?rin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2024 Jun; 7(3):438-446.
-
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Gu?rin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 12; 84(6):536-544.
-
Impact of age >70?years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu?rin. BJU Int. 2024 01; 133(1):63-70.